Zydus Lifesciences stock gets US generic launch

Published on 10/07/2026 at 07:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zydus Lifesciences stock was at INR 1,163.80 on October 7, 2026, 5.54 percent below its 52-week high. Q1 FY27 revenue reached INR 80.17 billion.

Zydus Lifesciences, INE010B01027, Illustration mit AI erstellt.

Zydus Lifesciences (ISIN INE010B01027) was trading at INR 1,163.80 on the NSE at 10:45 a.m. IST on October 7, 2026, up 0.37 percent from the prior close and 5.54 percent below its 52-week high of INR 1,232.10. The immediate company catalyst is a US specialty-drug launch that expands the company's complex-generics portfolio.

First generic reaches US market

On October 5, 2026, Zydus and MSN Laboratories launched the first generic version of Bayer's Adempas, or riociguat, in the United States. The PR Newswire release said the product is available in five strengths from 0.5 mg to 2.5 mg and has USFDA approval as a generic equivalent.

The commercial role is split between the partners. MSN developed and manufactures the tablets, while Zydus brings its US commercial platform to the launch. The product targets pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, two conditions for which the branded product had previously dominated the US market, according to CNBC TV18.

Revenue grows as profit stays central

Zydus reported Q1 FY27 consolidated revenue of INR 80.17 billion and net profit of INR 9.4 billion for the quarter ended June 30, 2026, figures carried by Zerodha from a Reuters report. Business Standard described overall revenue growth as 21 percent year over year and said domestic formulations grew more than 19.5 percent in the June quarter.

The growth mix is important because the higher-margin chronic portfolio accounted for 54 percent of trailing-12-month revenue, according to Business Standard. That figure was 360 basis points higher than four years earlier, giving the latest launch a broader portfolio context than a single-product announcement.

Valuation sets a tougher test

Nirmal Bang Research rated the stock Hold in the October 2, 2026 analysis cited by Business Standard and set a target price of INR 1,274. The brokerage expects revenue to rise from INR 27,150 crore in fiscal year 2026 to INR 33,480 crore in fiscal year 2028, an 11 percent annual growth rate, while flagging investment intensity and US business erosion as risks.

Stock remains below yearly high

Zydus Lifesciences stock was trading at INR 1,163.80 on the NSE on October 7, 2026, with a day range of INR 1,150 to INR 1,167.40 and a market capitalization of INR 1.2 trillion. The combination of a first-to-market US launch, 21 percent quarterly revenue growth and a Hold rating leaves execution and margin performance as the next measurable tests.